Improving Screening for Cystic Fibrosis–Related Diabetes at a Pediatric Cystic Fibrosis Program

Download (0)

Full text

(1)

Diabetes at a Pediatric Cystic Fibrosis Program

abstract

OBJECTIVE:Despite guidelines recommending an annual oral glucose tolerance test (OGTT) for all patients with cysticfibrosis (CF) aged$10 years, screening rates for cystic fibrosis–related diabetes (CFRD) remained low at our center. The aim of this project was to implement an outpatient system to provide effective, evidence-based screening for CFRD at a pediatric CF program.

METHODS:Development of a system to improve outpatient screening for CFRD included structured education, communication with families, and processes for scheduling laboratory appointments. The primary outcome measure was the proportion of eligible patients seen at the clinic who received an OGTT by the subsequent clinic appointment. The proportion of patients without CFRD in our program who received an OGTT within the previous 12 months was also tracked longitudinally.

RESULTS:The outpatient screening rate for CFRD increased from 2% of eligible patients seen at the clinic during the 18 weeks before the start of our initiative to 78% during the 18 weeks after the start of our ini-tiative (P , .001). The screening rate was also increased from the corresponding date range the previous year, when only 35% of eligible patients received an OGTT (P , .001). The overall percentage of patients without CFRD in our program who received an OGTT in the previous 12 months increased from 47% to 71% after implementation of our initiative (P= .003).

CONCLUSIONS:A systematic, quality improvement approach effectively increased the rate of outpatient screening for CFRD at a pediatric CF program.Pediatrics2013;132:e512–e518

AUTHORS:Andrew S. Kern, BA,aand Adrienne L.

Prestridge, MD, MSa,b

aDivision of Pulmonary Medicine, Ann & Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois; andbDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois

KEY WORDS

cysticfibrosis, diabetes mellitus, glucose tolerance test, quality improvement, screening

ABBREVIATIONS

CF—cysticfibrosis

CFF—Cystic Fibrosis Foundation CFRD—cysticfibrosis–related diabetes EMR—electronic medical record OGTT—oral glucose tolerance test QI—quality improvement

Mr Kern conceptualized and designed the study; contributed substantially to the acquisition, analysis, and interpretation of data; drafted the initial manuscript; critically reviewed and revised the manuscript; and approved thefinal manuscript as submitted. Dr Prestridge conceptualized and designed the study; contributed substantially to the acquisition, analysis, and interpretation of data; critically reviewed and revised the manuscript; and approved thefinal manuscript as submitted. www.pediatrics.org/cgi/doi/10.1542/peds.2012-4029

doi:10.1542/peds.2012-4029 Accepted for publication Apr 8, 2013

Address correspondence to Andrew S. Kern, c/o Dr Adrienne L. Prestridge, Division of Pulmonary Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, 225 East Chicago Ave, Box 43, Chicago, IL 60611-2605. E-mail: a-kern@fsm.northwestern.edu PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2013 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE:The authors have indicated they have nofinancial relationships relevant to this article to disclose.

(2)

Cysticfibrosis–related diabetes (CFRD) is 1 of the most common comorbidities associated with cysticfibrosis (CF) and is estimated to occur in∼20% of ado-lescents.1The impact of CFRD is broad and has been associated with decreased lung function, increased pulmonary ex-acerbations, poor nutritional outcomes, and decreased survival.2–5 Previous studies have demonstrated the benefit of early administration of therapy for CFRD,6thus stressing the importance of appropriate screening measures.

Annual screening for CFRD has been a longstanding recommendation in CF; however, it has not been easy to im-plement in clinical practice. The gold standard screening test of healthy outpatients is the oral glucose toler-ance test (OGTT), recommended by the Cystic Fibrosis Foundation (CFF) annu-ally for all patients with CF aged$10 years.7However, the national average screening rate was only 31.5% in 2011, and there was considerable variation in care delivery. This poor performance may in part reflect the logistical diffi -culty of obtaining the OGTT (fasting is required for at least 8 hours before the time of testing). Therefore, the majority of patients with upcom-ing late-mornupcom-ing or afternoon clinic appointments must schedule testing at a separate time. The requirement for venipuncture as part of the OGTT may also present a barrier to screening, considering the distress often associ-ated with blood draws in the pediatric population.8,9

Due to the aforementioned logistical concerns, our program only routinely offered the OGTT to patients who were already scheduled for early-morning appointments and were simulta-neously due for other blood work re-lated to their CF care. Outside of this limited subset of patients, however, we lacked a standardized system for pro-actively contacting families to ensure the timely scheduling of fasting tests in

the early morning. Consequently, de-spite an aggressive nutritional in-tervention program and heightened awareness of the importance of CFRD, our center’s annual OGTT screening rate failed to keep pace with the rising national average between 2009 and 2011 (Fig 1).10

The study questions central to our ini-tiative included: (1) How can we in-corporate a wider and more effective screening effort into our existing pre-paration for CF clinic appointments? (2) How can we ensure that patients en-couraged to receive an OGTT more re-liably complete the screening? Our aim was to implement a standardized screening procedure for CFRD in all patients with CF aged$10 years who were not currently treated with insulin.

METHODS

Setting

Ann & Robert H. Lurie Children’s Hos-pital of Chicago (Lurie Children’s) is a freestanding academic and urban pediatric medical center. The Cystic Fibrosis Center at Lurie Children’s is composed of a multidisciplinary team that currently manages 182 patients. Our team members share a strong

culture of quality improvement (QI), which facilitated our initiative’s de-velopment and success.

Improvement Team

The current QI initiative was designed as 1 component of a joint collaborative effort between our pediatric program and the Northwestern Memorial Hos-pital adult CF program addressing the screening, diagnosis, and treatment of CFRD. Specific improvement methods were developed independently by each program to meet the disparate needs of the pediatric and adult CF populations. At our site, the program’s co-director and a medical student who had pre-viously worked with the program led the improvement team. All other team members, including physicians and administrative staff, provided frequent collaboration and feedback at weekly team meetings. The support and par-ticipation of all team members in this initiative were instrumental in allowing for the comprehensive screening of patients in our program.

Ethical Concerns

Our program’s initiative was deter-mined to be QI work but was nonethe-less approved by the Lurie Children’s

FIGURE 1

OGTT screening rate in nondiabetic patients aged$10 years at the Northwestern University–Lurie Children’s Cystic Fibrosis Center (red) compared with the national average (green) and 10 best per-forming centers (blue), 2007 to 2011. Data provided by the CFF.10

(3)

patients were not offered the OGTT if the primary physician deemed such efforts incongruent with their overall care plan. Diagnostic criteria were consistent with the CFF and American Diabetes Association clinical care guide-lines for CFRD.7

Planning the Intervention

In early June 2012, the full Lurie Child-ren’s CF team was briefed on the initial QI plan. The CFRD Smart Change Com-pendium,11developed by participants of the 2010–2011Learning and Leader-ship Collaborative: CFRD, was consulted to gain insight into the experiences of other CF centers and to access re-sources shared across the CFF’s Care Center Network. Recommendations in-cluded in the compendium were then evaluated and adapted to meet the specific needs of our site.

Table 1 depicts key drivers that were believed to influence the effectiveness of CFRD screening at our program. The

Do-Study-Act cycle methods used for improvement and continuous modifi -cation throughout the initiative.12

Preclinic Interventions

Determining eligible patients: The OGTT was expanded to include eli-gible patients in all families re-gardless of appointment time or correspondence with annual labo-ratories. Patients were included in our screening effort if they were aged $10 years and had not re-ceived an OGTT in the past 12 months. Patients were excluded from screening if they had a diag-nosis of diabetes (CFRD, type 1 or type 2 diabetes) currently requir-ing insulin treatment. Because the OGTT is not recommended as a screening test for CFRD within 6 weeks of an acute illness,7 patients were also excluded if they were recovering from a“moderate” or“severe”pulmonary exacerbation,

termination of oral or, if initiated, intravenous antibiotic treatment.

Educational mailings: Previous re-search has demonstrated that postpartum postal reminders im-prove OGTT screening rates among new mothers with gestational dia-betes.13 Thus, for our initiative, a letter was similarly designed and sent to families 2 weeks before the week of the patient’s appointment. The letter included instructions for scheduling the test and enclosed an educational sheet describ-ing the OGTT and CFRD in-depth. Letters were mailed to English-speaking and Spanish-speaking families in the appropriate lan-guage. A process was developed enabling the primary nurse to electronically request a depart-mental administrative assistant to mail letters.

Scheduling: The clinical office as-sistant coordinated the scheduling of testing, which was previously a nursing responsibility. If the fam-ily of an eligible patient did not call the office to schedule an appoint-ment for OGTT, attempts to contact the family by telephone were made no later than the week before the patient’s clinic appointment. A fam-ily with a morning clinic appoint-ment was asked to initiate the OGTT before the clinic visit and was given instructions to prepare for the test. A family with an after-noon clinic appointment was asked to either reschedule the appoint-ment during a morning opening or to schedule a separate morn-ing laboratory-only appointment. If such an appointment change was not possible, the family was asked to schedule the subsequent clinic appointment in the morning. In an effort to ensure both adequate TABLE 1 Key Drivers Outlining Interventions Used to Achieve the Desired Aim

Key Drivers Interventions

Encouragement and scheduling of OGTT before clinic

•Approached patients for OGTT regardless of appointment time and correspondence with other blood work

•Moved order placement for OGTT and concurrent laboratories to the time of 2-wk preclinic chart screening

•Sent letters and educational enclosures, developed in English and Spanish, to families of patients identified for OGTT

•Placed follow-up telephone calls 1 wk before the clinic appointment to preschedule and provide preparatory instructions for the OGTT

Effective implementation of current OGTT •Worked with outpatient laboratory staff to incorporate the OGTT into routine clinic appointments

Communication with families concerning future required OGTTs

•Developed checklist of tests requiring scheduling before or at next visit for families to provide to staff on checkout

•Established procedure for implementing education about CFRD and the OGTT at clinic

Communication of OGTT results •Developed results letters in English and Spanish to communicate normal and abnormal results

•Automated the generation of results letters on the EMR

•Created the option to send results letters via a patient’s online personal health portal

Follow-up with family to rectify unscheduled OGTTs after the clinic visit

•Implemented more transparent physician documentation of future required tests

•Established a back-office process for reviewing and resolving unscheduled, required tests

(4)

laboratory supply of glucose solu-tion and families’ compliance with recommended OGTTs, we elimi-nated the practice of routinely of-fering walk-in OGTTs and instead requested that all families presched-ule the test. Our clinical office assis-tants were trained to schedule the tests directly on the electronic med-ical record (EMR) system in lieu of requesting appointments from the laboratory.

In-Clinic Interventions

Laboratory support: The staff lead-ership of the outpatient laborato-ries was consulted to formalize the system for conducting the OGTT, particularly within the context of routine CF clinic appointments. Process changes included more precise scheduling of blood draws in the EMR and laboratory docu-mentation of the completion of oral glucose solution.

Subsequent visit planning: A check-list of tests to be completed before or at the patient’s next clinic appoint-ment, including the OGTT, was de-veloped and incorporated into clinic processes. At the patient’s discharge from the clinic, the checklist was relayed to the family with instructions to provide the document to the scheduling staff at the checkout desk.

Education: The educational sheet enclosed with the preclinic letter was also introduced routinely in the clinic to reinforce knowledge about the OGTT and CFRD. In-clinic education was later transitioned into a component of regular nutri-tional assessments to be offered at the discretion of the patient’s phy-sician and dietitian.

Postclinic Interventions

Results notification: If the screen-ing test results were abnormal, the

primary medical team placed tele-phone calls to discuss the results and next steps in care. In addition, standardized letters intended to convey the results of the OGTT to families were developed. Multiple templated versions of the letters were designed in the EMR to ac-count for differing result clas-sifications (normal, impaired, or CFRD), primary languages of fam-ilies (English or Spanish), and pa-tient ages (minor or adult). Once abnormal results were relayed by telephone or if a patient’s test re-sults were normal, the letters were either mailed or posted onto the patient’s personal online health portal.

Closing the loop: A back-office pro-cess was implemented to ensure that patients who did not receive a recommended test such as an OGTT were scheduled for these remaining needs. A clinical office assistant identified such patients by comparing scheduled appoint-ments in the EMR with the physi-cian’s assessment and plan after every clinic appointment. Any dis-crepancies between recommended and scheduled tests were addressed by telephone calls requesting fami-lies to make the necessary appoint-ments.

Planning the Study of the Intervention

The primary outcome measure was the proportion of eligible patients seen in the clinic who received an OGTT by the subsequent clinic appointment. This parameter was calculated for each 2-week interval before and after the start of our initiative on June 15, 2012. Eligibility was based on the same criteria as the screening effort, modified only to exclude 10-year-olds, to whom the CFF recommendation for

an annual OGTT had not applied for a full 12 months.

To assess the performance of CFRD screening from a broader perspective, the proportion of all patients without CFRD in our program who received an OGTT in the past 12 months was tracked as a secondary outcome measure. Tracking of this measure was enabled through center-specific data on the CFF Patient Registry, a longitudinal, encounter-based database of multiple variables related to clinical status and treatment. Although the variable used in the Patient Registry is defined slightly differently than our primary outcome measure, it was nonetheless used to facilitate long-term monitoring that would ensure sustainability of our system.

Data Analysis

Screening rates were compared by using a 2-tailed Fisher’s exact test. Statistical analyses were performed by using Stata version 12.1 (StataCorp, College Station, TX). All results were considered statistically significant at P,.05.

RESULTS

Figure 2 displays the CFRD screening rate in 2-week intervals spanning the 18 weeks before and 18 weeks after the start of our initiative on June 15, 2012. As demonstrated, the screening rate improved dramatically during the postinitiative time period (June 15, 2012–October 18, 2012). Although the screening ratefluctuated, it remained substantially higher than during the preinitiative time period (February 20, 2012–June 14, 2012).

(5)

(78%) of 58 eligible patients received an OGTT during the postinitiative time period, a statistically significant in-crease (P,.001). However, the possi-bility that seasonal variation could confound the effect was considered, as the time-consuming OGTT is less bur-densome to complete in the summer months. Therefore, we compared the postinitiative screening rate with the corresponding date range the previous year (June 15, 2011–October 18, 2011). Table 2 shows that the postinitiative screening rate was more than twice

the corresponding 2011 rate (17 of 48 [35% of eligible patients]), which was also a statistically significant differ-ence (P,.001).

The quarterly data tracking shown in Table 3 enables a more global assess-ment of our CFRD screening program. As of June 2012, ,50% of patients without a previous CFRD diagnosis were current with the recommended annual OGTT when measured at the end of any quarter. At the end of the quarter that followed the full implementation of

our interventions (September 30, 2012), however, 71% of such patients had received an OGTT in the past 12 months, a significant increase from the most recent quarterly measurement before the implementation of our ini-tiative (47% on March 31, 2012;P= .003).

By the end of the calendar year 2012, 82% of eligible patients had been screened in the previous 12 months (Table 3). Of the 68 patients screened, 4 (6%) had an OGTT result consistent with CFRD, 16 (24%) had impaired glucose

TABLE 2 Postinitiative Outpatient OGTT Rate Compared With Baseline Time Periods

Patients Time Period

6/15/11–10/18/11 (Previous Year) 2/10/12–6/14/12 (Preinitiative) 6/15/12–10/18/12 (Postinitiative)

Eligible patients,n 48 46 58

Eligible patients screened,n(%) 17 (35) 1 (2) 45 (78)a

(6)

tolerance, and 48 (71%) had normal glucose tolerance.

DISCUSSION

The need for QI efforts to address dis-parate performance in CFRD screening and management across CF centers has long been voiced in the literature.14,15 Therefore, the aim of this QI initiative was to improve our pediatric pro-gram’s adherence to CFF guidelines for CFRD. After the implementation of our interventions, the proportion of patients receiving OGTT increased sig-nificantly according to multiple mea-sures used to evaluate our screening program. Based on the evidence, we believe that the observed improvement is directly attributable to our interven-tions. The apparent effectiveness of our interventions is consistent with success-ful past QI efforts by The Northern New England Cystic Fibrosis Consortium.15

The fact that our medical student, who was not a full-time team member, played an integral role in the planning and piloting of our efforts may raise questions about the sustainability of our initiative. To help mollify this con-cern, a detailed center playbook for outpatient CFRD screening was in-troduced to the pediatric team at the beginning of August 2012. Individual meetings were held with key team members, who were given versions of the playbook designed for their specific roles. A 2-week transition period en-abled the transfer of responsibilities

previously held by the medical student to other team members. After the medical student’s departure in mid-August, we continued to monitor our data and have experienced sustained levels of screening. By the end of 2012, we had performed screening on 82% of our patients in the past 12 months. Our center continues to track the data to monitor for slips in our success. Due to the high rate of screening, we have transitioned to monthly data assess-ment for the upcoming calendar year. If successful, we will then increase to quarterly monitoring of the data.

The interventions that were used to target communication with families, education, and scheduling processes helped our program obtain elevated screening rates for CFRD. These inter-ventions, however, are not just specific to CF; they are feasible to implement in any clinic for any screening test. Al-though we were fortunate to have a medical student who accelerated the rate of improvement by contributing dedicated time toward this effort, the entire process change and imple-mentation were completed in only 10 weeks. In addition, our CF program staff were well-versed in QI methods, and thus performing small tests of change was commonplace for our team. After the medical student left, the screening process became routine for the staff and consumed minimal additional time, while continued monitoring required ,1 hour per month to complete. Other sites may not have a dedicated

in-dividual to design and implement interventions in an accelerated time frame or have a team that is as familiar with QI processes as ours was; how-ever, the initiative could have been completed over a more extended pe-riod of time while still achieving the same results.

The QI methods adopted in this study confer some limitations. Specifically, the difficulty of definitively excluding external factors that may have con-tributed to the observed improvement in concert with our initiative constitutes a“history threat”to internal validity.16 However, the higher screening rate af-ter our initiative relative to the corre-sponding date range the previous year should mitigate concern that the im-provement is merely attributable to the initiative’s summertime implementa-tion. External validity is also limited due to the initiative’s implementation at a single CF program, where the geographic or financial barriers to obtaining OGTT may not be represen-tative of CF care at large. Other limi-tations stem from the shortcomings of our primary outcome measure: the proportion of eligible patients seen at the clinic who were screened before the subsequent clinic appointment. Because it was not possible to discern the pulmonary exacerbation status and thus the eligibility of patients who had rescheduled, canceled, or failed to ap-pear at appointments, such appoint-ments were excluded from screening rate calculations. However, this action may have inadvertently introduced self-selection bias, as families who re-liably attend appointments may be more amenable to the recommenda-tion for OGTT. The increase observed in our secondary outcome measure (ie, the total proportion of patients without CFRD screened in the past 12 months) therefore lends support to the effective-ness of our interventions in improving screening for CFRD.

TABLE 3 Percentage of Patients Aged$10 Years Without CFRD Receiving OGTT in Previous 12 Months (Measured Quarterly)

Date at End of Quarter No. Screened No. of Patients Percent Screened

3/31/2011 23 70 33

6/30/2011 27 73 37

9/30/2011 35 74 47

12/31/2011 30 74 41

3/31/2012 35 74 47

6/30/2012 36 76 47

9/30/2012 55 77 71a

12/31/2012 68 83 82

aP= .003 comparing the quarter ending 3/31/2012 with the quarter ending 9/30/2012 (Fishers exact test).

(7)

targeting education about CFRD and the OGTT, communication with families, and scheduling processes, was effective in improving the rate of screening for diabetes at our pediatric CF program. We encourage other QI teams, working both within and beyond CF care, to capitalize on such a strategy in their efforts to implement improvement plans. Future QI initiatives related to

inpatients hospitalized with CF exac-erbations for CFRD and investigating the clinical utility of nonfasting tests proposed as alternatives to the stan-dard OGTT.17–19

ACKNOWLEDGMENTS

We thank all team members of the Cystic Fibrosis Center at Lurie Children’s for their patience and feedback throughout

VandenBranden, Carolyn Heyman, Lisa McKinney, Kristen Leeke, Eileen Potter, Julie Nufer, Sylvia Guzman, Ana Perez, and Laura Busse for their efforts on this project. We also acknowledge Michelle Prickett for her guidance and are grateful to the contributors toLearning and Leadership Collabora-tive: CFRDfor the materials and expe-riences shared in their compendium.

REFERENCES

1. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cysticfibrosis-related diabetes: current trends in prevalence, in-cidence, and mortality. Diabetes Care. 2009;32(9):1626–1631

2. Cawood TJ, McKenna MJ, Gallagher CG, et al. Cystic fibrosis-related diabetes in adults.Ir Med J. 2006;99(3):83–86

3. Koch C, Rainisio M, Madessani U, et al; Investigators of the European Epidemio-logic Registry of Cystic Fibrosis. Presence of cysticfibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cysticfibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis.Pediatr Pulmonol. 2001;32(5):343– 350

4. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146(5):681–687

5. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cysticfibrosis.Diabetes Care. 2005;28 (9):2141–2144

6. Moran A, Pekow P, Grover P, et al; Cystic Fibrosis Related Diabetes Therapy Study Group. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic

fibrosis related diabetes therapy trial. Di-abetes Care. 2009;32(10):1783–1788

7. Moran A, Brunzell C, Cohen RC, et al; CFRD Guidelines Committee. Clinical care guidelines

for cysticfibrosis-related diabetes: a posi-tion statement of the American Diabetes Association and a clinical practice guide-line of the Cystic Fibrosis Foundation, en-dorsed by the Pediatric Endocrine Society.

Diabetes Care. 2010;33(12):2697–2708

8. Smith RW, Shah V, Goldman RD, Taddio A. Caregivers’ responses to pain in their children in the emergency department.

Arch Pediatr Adolesc Med. 2007;161(6): 578–582

9. Humphrey GB, Boon CM, van Linden van den Heuvell GF, van de Wiel HB. The oc-currence of high levels of acute behavioral distress in children and adolescents un-dergoing routine venipunctures.Pediatrics. 1992;90(1 pt 1):87–91

10. Center Specific Patient Registry Report for 2011. Bethesda, MD: Cystic Fibrosis Foun-dation; 2012

11. Nash J, Messier R, Casella SJ, et al;

Learning and Leadership Collaborative: CFRD. Cystic Fibrosis Related Diabetes (CFRD) Evidence Based Practice and Smart Change Idea Compendium 2012. Bethesda, MD: Cystic Fibrosis Foundation; McLean, VA: Pediatric Endocrine Society; Lebanon, NH: Dartmouth Institute Microsystem Academy; May 2012

12. Langley GJ. The Improvement Guide: A Practical Approach to Enhancing Organi-zational Performance. 1st ed. San Francisco, CA: Jossey-Bass Publishers; 1996

13. Clark HD, Graham ID, Karovitch A, Keely EJ. Do postal reminders increase postpartum

screening of diabetes mellitus in women with gestational diabetes mellitus? A ran-domized controlled trial. Am J Obstet Gynecol. 2009;200(6):634.e1–634.e7

14. Casella SJ. CFRD: Opportunities for Quality Improvement. Symposium session at the 24th Annual North American Cystic Fibrosis Conference, Baltimore Convention Center, Baltimore, Maryland, October 21–23, 2010.

Pediatr Pulmonol. 2010;45(suppl 33):151– 152

15. Quinton HB, O’Connor GT. Current issues in quality improvement in cysticfibrosis.Clin Chest Med. 2007;28(2):459–472

16. Cook TD, Campbell DT.Quasi-experimentation: Design & Analysis Issues for Field Settings. Chicago, IL: Rand McNally College Pub Co; 1979

17. Cullina JF, Prickett MH, Lam A, et al. Im-proving Screening for Adult CFRD: A Nurse Initiated Clinic Protocol. Poster session abstract presented at the 26th Annual North American Cystic Fibrosis Conference, Orange County Convention Center Orlando, Florida, October 11–13, 2012. Pediatr Pul-monol. 2012;47(suppl 35):426–427

18. Lee JM, Gebremariam A, Wu EL, LaRose J, Gurney JG. Evaluation of nonfasting tests to screen for childhood and adolescent dys-glycemia.Diabetes Care. 2011;34(12):2597– 2602

19. Lee KM, Miller RJ, Rosenberg FM, Kreisman SH. Evaluation of glucose tolerance in cystic

fibrosis: comparison of 50-g and 75-g tests.

(8)

DOI: 10.1542/peds.2012-4029 originally published online July 1, 2013;

2013;132;e512

Pediatrics

Andrew S. Kern and Adrienne L. Prestridge

Fibrosis Program

Related Diabetes at a Pediatric Cystic

Improving Screening for Cystic Fibrosis

Services

Updated Information &

http://pediatrics.aappublications.org/content/132/2/e512

including high resolution figures, can be found at:

References

http://pediatrics.aappublications.org/content/132/2/e512#BIBL

This article cites 14 articles, 6 of which you can access for free at:

Subspecialty Collections

sub

http://www.aappublications.org/cgi/collection/quality_improvement_

Quality Improvement

e_management_sub

http://www.aappublications.org/cgi/collection/administration:practic

Administration/Practice Management

http://www.aappublications.org/cgi/collection/diabetes_mellitus_sub

Diabetes Mellitus

http://www.aappublications.org/cgi/collection/endocrinology_sub

Endocrinology

following collection(s):

This article, along with others on similar topics, appears in the

Permissions & Licensing

http://www.aappublications.org/site/misc/Permissions.xhtml

in its entirety can be found online at:

Information about reproducing this article in parts (figures, tables) or

Reprints

http://www.aappublications.org/site/misc/reprints.xhtml

(9)

DOI: 10.1542/peds.2012-4029 originally published online July 1, 2013;

2013;132;e512

Pediatrics

Andrew S. Kern and Adrienne L. Prestridge

http://pediatrics.aappublications.org/content/132/2/e512

located on the World Wide Web at:

The online version of this article, along with updated information and services, is

by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

Figure

TABLE 1 Key Drivers Outlining Interventions Used to Achieve the Desired Aim

TABLE 1

Key Drivers Outlining Interventions Used to Achieve the Desired Aim p.3
FIGURE 2Proportion of eligible patients screened with an OGTT, shown in 2-week intervals before and after the start of our initiative (June 15, 2012)

FIGURE 2Proportion

of eligible patients screened with an OGTT, shown in 2-week intervals before and after the start of our initiative (June 15, 2012) p.5
TABLE 2 Postinitiative Outpatient OGTT Rate Compared With Baseline Time Periods

TABLE 2

Postinitiative Outpatient OGTT Rate Compared With Baseline Time Periods p.5
TABLE 3 Percentage of Patients Aged $10 Years Without CFRD Receiving OGTT in Previous 12Months (Measured Quarterly)

TABLE 3

Percentage of Patients Aged $10 Years Without CFRD Receiving OGTT in Previous 12Months (Measured Quarterly) p.6

References